Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improving survival models in healthcare: a novel matching approach.
Bertsimas D, Ning C, Lønning PE, Baba H, Endo I, Burkhart R, Aucejo FN, Balzer F, Kreis ME, Margonis GA. Bertsimas D, et al. Res Sq [Preprint]. 2024 Dec 12:rs.3.rs-5467577. doi: 10.21203/rs.3.rs-5467577/v1. Res Sq. 2024. PMID: 39711552 Free PMC article. Preprint.
ASO Visual Abstract: Evaluating Combinations of Biological and Clinicopathologic Factors Linked to Poor Outcomes in Resected Colorectal Liver Metastasis: An External Validation Study.
Sasaki K, Wang J, Kamphues C, Buettner S, Gagniere J, Ardilles V, Imai K, Wagner D, Pozios I, Papakonstantinou D, Pikoulis E, Antoniou E, Morioka D, Løes IM, Lønning PE, Kornprat P, Aucejo FN, Baba H, de Santibañes E, Kaczirek K, Burkhart R, Endo I, Beyer K, Kreis ME, Pawlik TM, Margonis GA. Sasaki K, et al. Ann Surg Oncol. 2025 Jan;32(1):454-455. doi: 10.1245/s10434-024-16436-w. Ann Surg Oncol. 2025. PMID: 39521737 No abstract available.
Evaluating Combinations of Biological and Clinicopathologic Factors Linked to Poor Outcomes in Resected Colorectal Liver Metastasis: An External Validation Study.
Sasaki K, Wang J, Kamphues C, Buettner S, Gagniere J, Ardilles V, Imai K, Wagner D, Pozios I, Papakonstantinou D, Pikoulis E, Antoniou E, Morioka D, Løes IM, Lønning PE, Kornprat P, Aucejo FN, Baba H, de Santibañes E, Kaczirek K, Burkhart R, Endo I, Beyer K, Kreis ME, Pawlik TM, Margonis GA. Sasaki K, et al. Ann Surg Oncol. 2025 Jan;32(1):408-417. doi: 10.1245/s10434-024-16319-0. Epub 2024 Oct 8. Ann Surg Oncol. 2025. PMID: 39377842
Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study.
Margonis GA, Wang JJ, Boerner T, Moretto R, Buettner S, Andreatos N, Gagnière J, Wagner D, Løes IM, Bergamo F, Pietrantonio F, Scartozzi M, Spallanzani A, Vincenzi B, Antoniou E, Pikoulis E, Sartore-Bianchi A, Stasinos G, Sasaki K, Pawlik TM, Orlandi A, Pella N, Fitschek F, Kaczirek K, Dupré A, Pozios I, Beyer K, Kornprat P, Aucejo FN, Burkhart R, Weiss MJ, Lønning PE, Poultsides G, Cremolini C, Kreis ME, D'Angelica M. Margonis GA, et al. Br J Surg. 2024 Jul 2;111(7):znae176. doi: 10.1093/bjs/znae176. Br J Surg. 2024. PMID: 39051667
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results.
Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å; InPreD Consortium; IMPRESS-Norway Consortium. Puco K, et al. Acta Oncol. 2024 May 23;63:379-384. doi: 10.2340/1651-226X.2024.28322. Acta Oncol. 2024. PMID: 38779911 Free PMC article.
[Raising the quality of cancer treatment].
Helland Å, Steinskog ESS, Blix ES, Flobak Å, Brabrand S, Puco K, Niehusmann P, Meltzer S, Oppedal IA, Haug Å, Torkildsen CF, Randen U, Gilje B, Lønning PE, Gjertsen BT, Hovland R, Russnes HG, Fagereng GL, Smeland S, Tasken K. Helland Å, et al. Tidsskr Nor Laegeforen. 2024 Jan 18;144(1). doi: 10.4045/tidsskr.23.0740. Print 2024 Jan 23. Tidsskr Nor Laegeforen. 2024. PMID: 38258713 Free article. Norwegian. No abstract available.
Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.
Yndestad S, Engebrethsen C, Herencia-Ropero A, Nikolaienko O, Vintermyr OK, Lillestøl RK, Minsaas L, Leirvaag B, Iversen GT, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Aase HS, Aas T, Gudlaugsson EG, Llop-Guevara A, Serra V, Janssen EAM, Lønning PE, Knappskog S, Eikesdal HP. Yndestad S, et al. JCO Precis Oncol. 2023 Sep;7:e2300338. doi: 10.1200/PO.23.00338. JCO Precis Oncol. 2023. PMID: 38039432 Free PMC article.
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Electronic address: bc.overview@ctsu.ox.ac.uk, et al. Lancet. 2023 Apr 15;401(10384):1277-1292. doi: 10.1016/S0140-6736(23)00285-4. Lancet. 2023. PMID: 37061269 Free PMC article.
Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions.
Margonis GA, Boerner T, Bachet JB, Buettner S, Moretto R, Andreatos N, Sartore-Bianchi A, Wang J, Kamphues C, Gagniere J, Lonardi S, Løes IM, Wagner D, Spallanzani A, Sasaki K, Burkhart R, Pietrantonio F, Pikoulis E, Pawlik TM, Truant S, Orlandi A, Pikouli A, Pella N, Beyer K, Poultsides G, Seeliger H, Aucejo FN, Kornprat P, Kaczirek K, Lønning PE, Kreis ME, Wolfgang CL, Weiss MJ, Cremolini C, Benoist S, D'Angelica M. Margonis GA, et al. Ann Surg. 2023 Sep 1;278(3):e540-e548. doi: 10.1097/SLA.0000000000005771. Epub 2022 Dec 1. Ann Surg. 2023. PMID: 36453261 Free PMC article.
APOBEC3A/B deletion polymorphism and endometrial cancer risk.
Sofiyeva N, Krakstad C, Halle MK, O'Mara TA, Romundstad P, Hveem K, Vatten L, Lønning PE, Gansmo LB, Knappskog S. Sofiyeva N, et al. Cancer Med. 2023 Mar;12(6):6659-6667. doi: 10.1002/cam4.5448. Epub 2022 Nov 16. Cancer Med. 2023. PMID: 36394079 Free PMC article.
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers.
Batalini F, Gulhan DC, Mao V, Tran A, Polak M, Xiong N, Tayob N, Tung NM, Winer EP, Mayer EL, Knappskog S, Lønning PE, Matulonis UA, Konstantinopoulos PA, Solit DB, Won H, Eikesdal HP, Park PJ, Wulf GM. Batalini F, et al. Clin Cancer Res. 2022 Nov 1;28(21):4714-4723. doi: 10.1158/1078-0432.CCR-22-0749. Clin Cancer Res. 2022. PMID: 36048535 Free PMC article.
Using Artificial Intelligence to Find the Optimal Margin Width in Hepatectomy for Colorectal Cancer Liver Metastases.
Bertsimas D, Margonis GA, Sujichantararat S, Boerner T, Ma Y, Wang J, Kamphues C, Sasaki K, Tang S, Gagniere J, Dupré A, Løes IM, Wagner D, Stasinos G, Macher-Beer A, Burkhart R, Morioka D, Imai K, Ardiles V, O'Connor JM, Pawlik TM, Poultsides G, Seeliger H, Beyer K, Kaczirek K, Kornprat P, Aucejo FN, de Santibañes E, Baba H, Endo I, Lønning PE, Kreis ME, Weiss MJ, Wolfgang CL, D'Angelica M. Bertsimas D, et al. JAMA Surg. 2022 Aug 1;157(8):e221819. doi: 10.1001/jamasurg.2022.1819. Epub 2022 Aug 10. JAMA Surg. 2022. PMID: 35648428 Free PMC article.
KRAS alterations in colorectal liver metastases: shifting to exon, codon, and point mutations.
Olthof PB, Buettner S, Andreatos N, Wang J, Løes IM, Wagner D, Sasaki K, Macher-Beer A, Kamphues C, Pozios I, Seeliger H, Morioka D, Imai K, Kaczirek K, Pawlik TM, Poultsides G, Burkhart R, Endo I, Baba H, Kornprat P, Aucejo FN, Lønning PE, Beyer K, Weiss MJ, Wolfgang CL, Kreis ME, Margonis GA. Olthof PB, et al. Br J Surg. 2022 Aug 16;109(9):804-807. doi: 10.1093/bjs/znac147. Br J Surg. 2022. PMID: 35595182 Free PMC article. No abstract available.
A national precision cancer medicine implementation initiative for Norway.
Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public–Private Partnership Consortium; Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R; InPreD-Norway and National Molecular Tumor Board Consortium; IMPRESS-Norway Consortium; Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å. Taskén K, et al. Nat Med. 2022 May;28(5):885-887. doi: 10.1038/s41591-022-01777-4. Nat Med. 2022. PMID: 35513529 No abstract available.
Mutant KRAS as a prognostic biomarker after hepatectomy for rectal cancer metastases: Does the primary disease site matter?
Amini N, Andreatos N, Margonis GA, Buettner S, Wang J, Galjart B, Wagner D, Sasaki K, Angelou A, Sun J, Kamphues C, Beer A, Morioka D, Løes IM, Antoniou E, Imai K, Pikoulis E, He J, Kaczirek K, Poultsides G, Verhoef C, Lønning PE, Endo I, Baba H, Kornprat P, NAucejo F, Kreis ME, Christopher WL, Weiss MJ, Safar B, Burkhart RA. Amini N, et al. J Hepatobiliary Pancreat Sci. 2022 Apr;29(4):417-427. doi: 10.1002/jhbp.1054. Epub 2021 Oct 20. J Hepatobiliary Pancreat Sci. 2022. PMID: 34614304
Letter to the Editor.
Lønning PE. Lønning PE. J Steroid Biochem Mol Biol. 2021 Sep;212:105919. doi: 10.1016/j.jsbmb.2021.105919. Epub 2021 May 21. J Steroid Biochem Mol Biol. 2021. PMID: 34023394 No abstract available.
Performance of two prognostic scores that incorporate genetic information to predict long-term outcomes following resection of colorectal cancer liver metastases: An external validation of the MD Anderson and JHH-MSK scores.
Sasaki K, Gagnière J, Dupré A, Ardiles V, O'Connor JM, Wang J, Moro A, Morioka D, Buettner S, Gau L, Ribeiro M, Wagner D, Andreatos N, Løes IM, Fitschek F, Kaczirek K, Lønning PE, Kornprat P, Poultsides G, Kamphues C, Imai K, Baba H, Endo I, Kwon CHD, Aucejo FN, de Santibañes E, Kreis ME, Margonis GA. Sasaki K, et al. J Hepatobiliary Pancreat Sci. 2021 Jul;28(7):581-592. doi: 10.1002/jhbp.963. Epub 2021 Apr 24. J Hepatobiliary Pancreat Sci. 2021. PMID: 33797866
The optimal cut-off values for tumor size, number of lesions, and CEA levels in patients with surgically treated colorectal cancer liver metastases: An international, multi-institutional study.
Kamphues C, Andreatos N, Kruppa J, Buettner S, Wang J, Sasaki K, Wagner D, Morioka D, Fitschek F, Løes IM, Imai K, Sun J, Poultsides G, Kaczirek K, Lønning PE, Endo I, Baba H, Kornprat P, Aucejo FN, Wolfgang CL, Kreis ME, Weiss MJ, Margonis GA. Kamphues C, et al. J Surg Oncol. 2021 Mar;123(4):939-948. doi: 10.1002/jso.26361. Epub 2021 Jan 5. J Surg Oncol. 2021. PMID: 33400818
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE. Eikesdal HP, et al. Ann Oncol. 2021 Feb;32(2):240-249. doi: 10.1016/j.annonc.2020.11.009. Epub 2020 Nov 24. Ann Oncol. 2021. PMID: 33242536 Free article. Clinical Trial.
The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis.
Margonis GA, Amini N, Buettner S, Kim Y, Wang J, Andreatos N, Wagner D, Sasaki K, Beer A, Kamphues C, Morioka D, Løes IM, Imai K, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Burkhart R, Endo I, Baba H, Mischinger HJ, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ. Margonis GA, et al. Ann Surg. 2021 Jun 1;273(6):1165-1172. doi: 10.1097/SLA.0000000000003504. Ann Surg. 2021. PMID: 31389831
Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC.
Røsland GV, Dyrstad SE, Tusubira D, Helwa R, Tan TZ, Lotsberg ML, Pettersen IKN, Berg A, Kindt C, Hoel F, Jacobsen K, Arason AJ, Engelsen AST, Ditzel HJ, Lønning PE, Krakstad C, Thiery JP, Lorens JB, Knappskog S, Tronstad KJ. Røsland GV, et al. Cancer Metab. 2019 Jun 1;7:6. doi: 10.1186/s40170-019-0197-8. eCollection 2019. Cancer Metab. 2019. PMID: 31164982 Free PMC article.
Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 Patients.
Margonis GA, Buettner S, Andreatos N, Wagner D, Sasaki K, Barbon C, Beer A, Kamphues C, Løes IM, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Mischinger HJ, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ. Margonis GA, et al. Ann Surg. 2019 Jun;269(6):1129-1137. doi: 10.1097/SLA.0000000000002664. Ann Surg. 2019. PMID: 31082912
Human endotrophin as a driver of malignant tumor growth.
Bu D, Crewe C, Kusminski CM, Gordillo R, Ghaben AL, Kim M, Park J, Deng H, Xiong W, Liu XZ, Lønning PE, Halberg N, Rios A, Chang Y, Gonzalez A, Zhang N, An Z, Scherer PE. Bu D, et al. JCI Insight. 2019 Mar 21;5(9):e125094. doi: 10.1172/jci.insight.125094. JCI Insight. 2019. PMID: 30896449 Free PMC article.
Patterns of genomic evolution in advanced melanoma.
Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O, Knappskog S, Lønning PE. Birkeland E, et al. Nat Commun. 2018 Jul 10;9(1):2665. doi: 10.1038/s41467-018-05063-1. Nat Commun. 2018. PMID: 29991680 Free PMC article.
Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Løes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ. Margonis GA, et al. JAMA Surg. 2018 Jul 18;153(7):e180996. doi: 10.1001/jamasurg.2018.0996. Epub 2018 Jul 18. JAMA Surg. 2018. PMID: 29799910 Free PMC article.
Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series.
Deshwar A, Margonis GA, Andreatos N, Barbon C, Wang J, Buettner S, Wagner D, Sasaki K, Beer A, Løes IM, Pikoulis E, Damaskos C, Garmpis N, Kamphues K, He J, Kaczirek K, Poultsides G, Lønning PE, Mischinger HJ, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ. Deshwar A, et al. Anticancer Res. 2018 May;38(5):2891-2895. doi: 10.21873/anticanres.12535. Anticancer Res. 2018. PMID: 29715113
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.
Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans G, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S. Lønning PE, et al. Ann Intern Med. 2018 Mar 6;168(5):326-334. doi: 10.7326/M17-0101. Epub 2018 Jan 16. Ann Intern Med. 2018. PMID: 29335712
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O'Regan R, Mouret-Reynier MA, Kalev D, Egle D, Csőszi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D, Bachelot T. Di Leo A, et al. Lancet Oncol. 2018 Jan;19(1):87-100. doi: 10.1016/S1470-2045(17)30688-5. Epub 2017 Dec 7. Lancet Oncol. 2018. PMID: 29223745 Clinical Trial.
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
Cheang MCU, Bliss JM, Viale G, Speirs V, Palmieri C, Shaaban A, Lønning PE, Morden J, Porta N, Jassem J, van De Velde CJ, Rasmussen BB, Verhoeven D, Bartlett JMS, Coombes RC; PathIES Sub-Committee. Cheang MCU, et al. Breast Cancer Res Treat. 2018 Feb;168(1):169-178. doi: 10.1007/s10549-017-4543-7. Epub 2017 Nov 24. Breast Cancer Res Treat. 2018. PMID: 29177605 Free PMC article. Clinical Trial.
APOBEC3A/B deletion polymorphism and cancer risk.
Gansmo LB, Romundstad P, Hveem K, Vatten L, Nik-Zainal S, Lønning PE, Knappskog S. Gansmo LB, et al. Carcinogenesis. 2018 Feb 9;39(2):118-124. doi: 10.1093/carcin/bgx131. Carcinogenesis. 2018. PMID: 29140415 Free PMC article.
Genomic Evolution of Breast Cancer Metastasis and Relapse.
Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I, Alexandrov LB, Van Loo P, Haugland HK, Lilleng PK, Gundem G, Gerstung M, Pappaemmanuil E, Gazinska P, Bhosle SG, Jones D, Raine K, Mudie L, Latimer C, Sawyer E, Desmedt C, Sotiriou C, Stratton MR, Sieuwerts AM, Lynch AG, Martens JW, Richardson AL, Tutt A, Lønning PE, Campbell PJ. Yates LR, et al. Cancer Cell. 2017 Aug 14;32(2):169-184.e7. doi: 10.1016/j.ccell.2017.07.005. Cancer Cell. 2017. PMID: 28810143 Free PMC article.
Long-Term Follow-Up of the Intergroup Exemestane Study.
Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC. Morden JP, et al. J Clin Oncol. 2017 Aug 1;35(22):2507-2514. doi: 10.1200/JCO.2016.70.5640. Epub 2017 May 3. J Clin Oncol. 2017. PMID: 28467729 Free PMC article. Clinical Trial.
DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.
Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN. Fleischer T, et al. Oncotarget. 2017 Jan 3;8(1):1074-1082. doi: 10.18632/oncotarget.13718. Oncotarget. 2017. PMID: 27911866 Free PMC article.
rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk.
Liu J, Lončar I, Collée JM, Bolla MK, Dennis J, Michailidou K, Wang Q, Andrulis IL, Barile M, Beckmann MW, Behrens S, Benitez J, Blomqvist C, Boeckx B, Bogdanova NV, Bojesen SE, Brauch H, Brennan P, Brenner H, Broeks A, Burwinkel B, Chang-Claude J, Chen ST, Chenevix-Trench G, Cheng CY, Choi JY, Couch FJ, Cox A, Cross SS, Cuk K, Czene K, Dörk T, Dos-Santos-Silva I, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Glendon G, Goldberg MS, González-Neira A, Guénel P, Haiman CA, Hamann U, Hart SN, Hartman M, Hatse S, Hopper JL, Ito H, Jakubowska A, Kabisch M, Kang D, Kosma VM, Kristensen VN, Le Marchand L, Lee E, Li J, Lophatananon A, Jan Lubinski, Mannermaa A, Matsuo K, Milne RL; NBCS Collaborators; Neuhausen SL, Nevanlinna H, Orr N, Perez JI, Peto J, Putti TC, Pylkäs K, Radice P, Sangrajrang S, Sawyer EJ, Schmidt MK, Schneeweiss A, Shen CY, Shrubsole MJ, Shu XO, Simard J, Southey MC, Swerdlow A, Teo SH, Tessier DC, Thanasitthichai S, Tomlinson I, Torres D, Truong T, Tseng CC, Vachon C, Winqvist R, Wu AH, Yannoukakos D, Zheng W, Hall P, Dunning AM, Easton DF, Hooning MJ, van den Ouweland AM, Martens JW, Hollestelle A. Liu J, et al. Sci Rep. 2016 Nov 15;6:36874. doi: 10.1038/srep36874. Sci Rep. 2016. PMID: 27845421 Free PMC article.
Prevalence of the CHEK2 R95* germline mutation.
Knappskog S, Leirvaag B, Gansmo LB, Romundstad P, Hveem K, Vatten L, Lønning PE. Knappskog S, et al. Hered Cancer Clin Pract. 2016 Sep 27;14:19. doi: 10.1186/s13053-016-0059-0. eCollection 2016. Hered Cancer Clin Pract. 2016. PMID: 27708748 Free PMC article.
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Flågeng MH, Larionov A, Geisler J, Knappskog S, Prestvik WS, Bjørkøy G, Lilleng PK, Dixon JM, Miller WR, Lønning PE, Mellgren G. Flågeng MH, et al. J Steroid Biochem Mol Biol. 2017 Jan;165(Pt B):228-235. doi: 10.1016/j.jsbmb.2016.06.011. Epub 2016 Jun 22. J Steroid Biochem Mol Biol. 2017. PMID: 27343990
Subclonal diversification of primary breast cancer revealed by multiregion sequencing.
Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, Li Y, Ju YS, Ramakrishna M, Haugland HK, Lilleng PK, Nik-Zainal S, McLaren S, Butler A, Martin S, Glodzik D, Menzies A, Raine K, Hinton J, Jones D, Mudie LJ, Jiang B, Vincent D, Greene-Colozzi A, Adnet PY, Fatima A, Maetens M, Ignatiadis M, Stratton MR, Sotiriou C, Richardson AL, Lønning PE, Wedge DC, Campbell PJ. Yates LR, et al. Nat Med. 2015 Jul;21(7):751-9. doi: 10.1038/nm.3886. Epub 2015 Jun 22. Nat Med. 2015. PMID: 26099045 Free PMC article.
Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.
Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE. Knappskog S, et al. Mol Oncol. 2015 Oct;9(8):1553-64. doi: 10.1016/j.molonc.2015.04.008. Epub 2015 May 8. Mol Oncol. 2015. PMID: 26004085 Free PMC article.
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†.
Speirs V, Viale G, Mousa K, Palmieri C, Reed SN, Nicholas H, Cheang M, Jassem J, Lønning PE, Kalaitzaki E, van de Velde CJH, Rasmussen BB, Verhoeven DM, Shaaban AM, Bartlett JMS, Bliss JM, Coombes RC; PathIES Sub-Committee. Speirs V, et al. Ann Oncol. 2015 Sep;26(9):1890-1897. doi: 10.1093/annonc/mdv242. Epub 2015 May 22. Ann Oncol. 2015. PMID: 26002610 Free article. Clinical Trial.
Normal breast tissue estrogen levels.
Lønning PE. Lønning PE. Maturitas. 2015 Jun;81(2):327. doi: 10.1016/j.maturitas.2015.03.005. Epub 2015 Mar 16. Maturitas. 2015. PMID: 25864130 No abstract available.
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.
Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, Maranian MJ, Bolla MK, Wang Q, Shah M, Perkins BJ, Czene K, Eriksson M, Darabi H, Brand JS, Bojesen SE, Nordestgaard BG, Flyger H, Nielsen SF, Rahman N, Turnbull C; BOCS; Fletcher O, Peto J, Gibson L, dos-Santos-Silva I, Chang-Claude J, Flesch-Janys D, Rudolph A, Eilber U, Behrens S, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Khan S, Aaltonen K, Ahsan H, Kibriya MG, Whittemore AS, John EM, Malone KE, Gammon MD, Santella RM, Ursin G, Makalic E, Schmidt DF, Casey G, Hunter DJ, Gapstur SM, Gaudet MM, Diver WR, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Berg CD, Chanock SJ, Figueroa J, Hoover RN, Lambrechts D, Neven P, Wildiers H, van Limbergen E, Schmidt MK, Broeks A, Verhoef S, Cornelissen S, Couch FJ, Olson JE, Hallberg E, Vachon C, Waisfisz Q, Meijers-Heijboer H, Adank MA, van der Luijt RB, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Yoo KY, Matsuo K, Ito H, Iwata H, Tajima K, Guénel P, Truong T, Mulot C, Sanchez M, Burwinkel B, Marme F, Surowy H, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, González-Neira A, Benitez J, Zamora MP, Perez JI, Shu XO, Lu W, Gao YT, Cai H, Cox A, Cr… See abstract for full author list ➔ Michailidou K, et al. Nat Genet. 2015 Apr;47(4):373-80. doi: 10.1038/ng.3242. Epub 2015 Mar 9. Nat Genet. 2015. PMID: 25751625 Free PMC article.
Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.
Lauss M, Haq R, Cirenajwis H, Phung B, Harbst K, Staaf J, Rosengren F, Holm K, Aine M, Jirström K, Borg Å, Busch C, Geisler J, Lønning PE, Ringnér M, Howlin J, Fisher DE, Jönsson G. Lauss M, et al. J Invest Dermatol. 2015 Jul;135(7):1820-1828. doi: 10.1038/jid.2015.61. Epub 2015 Feb 23. J Invest Dermatol. 2015. PMID: 25705847 Free PMC article.
Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649).
Knappskog S, Gansmo LB, Dibirova K, Metspalu A, Cybulski C, Peterlongo P, Aaltonen L, Vatten L, Romundstad P, Hveem K, Devilee P, Evans GD, Lin D, Van Camp G, Manolopoulos VG, Osorio A, Milani L, Ozcelik T, Zalloua P, Mouzaya F, Bliznetz E, Balanovska E, Pocheshkova E, Kučinskas V, Atramentova L, Nymadawa P, Titov K, Lavryashina M, Yusupov Y, Bogdanova N, Koshel S, Zamora J, Wedge DC, Charlesworth D, Dörk T, Balanovsky O, Lønning PE. Knappskog S, et al. Oncotarget. 2014 Sep 30;5(18):8223-34. doi: 10.18632/oncotarget.1910. Oncotarget. 2014. PMID: 25327560 Free PMC article.
DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors.
Klajic J, Busato F, Edvardsen H, Touleimat N, Fleischer T, Bukholm I, Børresen-Dale AL, Lønning PE, Tost J, Kristensen VN. Klajic J, et al. Clin Cancer Res. 2014 Dec 15;20(24):6357-66. doi: 10.1158/1078-0432.CCR-14-0297. Epub 2014 Oct 7. Clin Cancer Res. 2014. PMID: 25294903
MDM2 SNP309 and risk of endometrial cancer.
Knappskog S, Lønning PE. Knappskog S, et al. Tumour Biol. 2014 Aug;35(8):7285-6. doi: 10.1007/s13277-014-2244-y. Epub 2014 Jun 26. Tumour Biol. 2014. PMID: 24964960 Free article. No abstract available.
MDM2 SNP309 and risk of cervical cancer.
Knappskog S, Lønning PE. Knappskog S, et al. Tumour Biol. 2014 Jul;35(7):6185-6. doi: 10.1007/s13277-014-1910-4. Epub 2014 Apr 17. Tumour Biol. 2014. PMID: 24740562 Free article. No abstract available.
Signatures of mutational processes in human cancer.
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain; Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Alexandrov LB, et al. Nature. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14. Nature. 2013. PMID: 23945592 Free PMC article.
MDM2 SNP309 and risk of endometrial cancer.
Knappskog S, Lønning PE. Knappskog S, et al. Pol J Pathol. 2013 Apr;64(1):69-70. doi: 10.5114/pjp.2013.34607. Pol J Pathol. 2013. PMID: 23625604 Free article. No abstract available.
[Genome sequencing for personalized cancer treatment].
Skotheim RI, Meza-Zepeda LA, Hovig E, Lønning PE, Lothe RA, Myklebost O. Skotheim RI, et al. Tidsskr Nor Laegeforen. 2012 Nov 12;132(21):2406-8. doi: 10.4045/tidsskr.12.0784. Tidsskr Nor Laegeforen. 2012. PMID: 23160594 Free article. Norwegian. No abstract available.
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.
Knappskog S, Gansmo LB, Romundstad P, Bjørnslett M, Trovik J, Sommerfelt-Pettersen J, Løkkevik E; Norwegian Breast Cancer Group trial NBCG VI; Tollenaar RA, Seynaeve C, Devilee P, Salvesen HB, Dørum A, Hveem K, Vatten L, Lønning PE. Knappskog S, et al. PLoS One. 2012;7(4):e36263. doi: 10.1371/journal.pone.0036263. Epub 2012 Apr 30. PLoS One. 2012. PMID: 22558411 Free PMC article.
Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.
Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC. Bliss JM, et al. J Clin Oncol. 2012 Mar 1;30(7):709-17. doi: 10.1200/JCO.2010.33.7899. Epub 2011 Oct 31. J Clin Oncol. 2012. PMID: 22042946 Clinical Trial.
Vascular proliferation is a prognostic factor in breast cancer.
Arnes JB, Stefansson IM, Straume O, Baak JP, Lønning PE, Foulkes WD, Akslen LA. Arnes JB, et al. Breast Cancer Res Treat. 2012 Jun;133(2):501-10. doi: 10.1007/s10549-011-1785-7. Epub 2011 Sep 27. Breast Cancer Res Treat. 2012. PMID: 21947750
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE. Chrisanthar R, et al. PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249. PLoS One. 2011. PMID: 21556366 Free PMC article. Clinical Trial.
Recent data on intratumor estrogens in breast cancer.
Lønning PE, Haynes BP, Straume AH, Dunbier A, Helle H, Knappskog S, Dowsett M. Lønning PE, et al. Steroids. 2011 Jul;76(8):786-91. doi: 10.1016/j.steroids.2011.02.040. Epub 2011 Mar 31. Steroids. 2011. PMID: 21439992 Review.
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, Guo Y, Zhang X, Yang M, Ylisaukko-Oja SK, Alhopuro P, Arola J, Tollenaar RA, van Asperen CJ, Seynaeve C, Staalesen V, Chrisanthar R, Løkkevik E, Salvesen HB, Evans DG, Newman WG, Lin D, Aaltonen LA, Børresen-Dale AL, Tell GS, Stoltenberg C, Romundstad P, Hveem K, Lillehaug JR, Vatten L, Devilee P, Dørum A, Lønning PE. Knappskog S, et al. Cancer Cell. 2011 Feb 15;19(2):273-82. doi: 10.1016/j.ccr.2010.12.019. Cancer Cell. 2011. PMID: 21316605 Free article.
Controversies in Breast Cancer 2010. Session 6 introduction.
Robertson JF, Lønning PE. Robertson JF, et al. Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S15. doi: 10.1186/bcr2744. Breast Cancer Res. 2010. PMID: 21172077 Free PMC article. No abstract available.
Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter.
Torsvik A, Røsland GV, Svendsen A, Molven A, Immervoll H, McCormack E, Lønning PE, Primon M, Sobala E, Tonn JC, Goldbrunner R, Schichor C, Mysliwietz J, Lah TT, Motaln H, Knappskog S, Bjerkvig R. Torsvik A, et al. Cancer Res. 2010 Aug 1;70(15):6393-6. doi: 10.1158/0008-5472.CAN-10-1305. Epub 2010 Jul 14. Cancer Res. 2010. PMID: 20631079 No abstract available.
Molecular basis for therapy resistance.
Lønning PE. Lønning PE. Mol Oncol. 2010 Jun;4(3):284-300. doi: 10.1016/j.molonc.2010.04.005. Epub 2010 Apr 24. Mol Oncol. 2010. PMID: 20466604 Free PMC article. Review.
Intratumoral estrogen disposition in breast cancer.
Haynes BP, Straume AH, Geisler J, A'Hern R, Helle H, Smith IE, Lønning PE, Dowsett M. Haynes BP, et al. Clin Cancer Res. 2010 Mar 15;16(6):1790-801. doi: 10.1158/1078-0432.CCR-09-2481. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215536
Endocrine effects of aromatase inhibitors.
Lønning PE, Dowsett M. Lønning PE, et al. J Clin Oncol. 2010 Feb 20;28(6):e101-2; author reply e103-4. doi: 10.1200/JCO.2009.26.8268. Epub 2010 Jan 19. J Clin Oncol. 2010. PMID: 20085930 No abstract available.
A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide.
Glynn SA, Boersma BJ, Howe TM, Edvardsen H, Geisler SB, Goodman JE, Ridnour LA, Lønning PE, Børresen-Dale AL, Naume B, Kristensen VN, Chanock SJ, Wink DA, Ambs S. Glynn SA, et al. Clin Cancer Res. 2009 Jun 15;15(12):4165-73. doi: 10.1158/1078-0432.CCR-09-0119. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509150 Free PMC article.
Aromatase inhibition versus placebo.
Lønning PE. Lønning PE. Clin Breast Cancer. 2008 Aug;8(4):374. doi: 10.1016/S1526-8209(11)70534-1. Clin Breast Cancer. 2008. PMID: 18757268 No abstract available.
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE. Chrisanthar R, et al. PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062. PLoS One. 2008. PMID: 18725978 Free PMC article.
Aromatase inhibitors--socioeconomical issues.
Lønning PE, Geisler J. Lønning PE, et al. J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):55-61. doi: 10.1016/j.jsbmb.2007.05.002. Epub 2007 May 24. J Steroid Biochem Mol Biol. 2007. PMID: 17604616
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study. Coombes RC, et al. Lancet. 2007 Feb 17;369(9561):559-70. doi: 10.1016/S0140-6736(07)60200-1. Lancet. 2007. PMID: 17307102 Clinical Trial.
ABCB1 and GST polymorphisms associated with TP53 status in breast cancer.
Nordgard SH, Ritchie MD, Jensrud SD, Motsinger AA, Alnaes GI, Lemmon G, Berg M, Geisler S, Moore JH, Lønning PE, Børresen-Dale AL, Kristensen VN. Nordgard SH, et al. Pharmacogenet Genomics. 2007 Feb;17(2):127-36. doi: 10.1097/FPC.0b013e328011abaa. Pharmacogenet Genomics. 2007. PMID: 17301692
The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.
Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Børresen-Dale AL, Lillehaug JR, Lønning PE. Staalesen V, et al. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6000-4. doi: 10.1158/1078-0432.CCR-05-2822. Clin Cancer Res. 2006. PMID: 17062672
391 results